 CytoDyn Inc has announced treatment of the first patient in its pivotal Phase 3 trial CD16 in Brazil for critically ill Coronavirus COVID-19 patients, which it is conducting with Brazils BIOMM and academic research organisation ARO. The Vancouver, Washington-based late-stage biotechnology company said an interim analysis will be conducted 28 days following the enrollment of 127 patients. 